Plasma exchange after initial intravenous immunoglobulin treatment in Guillain-Barre syndrome: critical reassessment of effectiveness and cost-efficiency


Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details

DOI
10.1097/CND.0b013e3181f3dbbf

Indexing Status
Subject indexing assigned by CRD

MeSH
Cost-Benefit Analysis; Guillain-Barre Syndrome; Humans; Immunoglobulins, Intravenous; Plasma Exchange

AccessionNumber
22011000308

Date bibliographic record published
16/03/2011